Biblio

Kim J-YV, Tillu DV, Quinn TL, Mejia GL, Shy A, Asiedu MNK, Murad E, Schumann AP, Totsch SK, Sorge RE et al..  2015.  Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism.. J Neurosci. 35(16):6307-17.

Marshall TM, Herman DS, Largent-Milnes TM, Badghisi H, Zuber K, Holt SC, Lai J, Porreca F, Vanderah TW.  2012.  Activation of descending pain-facilitatory pathways from the rostral ventromedial medulla by cholecystokinin elicits release of prostaglandin-E₂ in the spinal cord.. Pain. 153(1):86-94.

De Felice M, Melchiorri P, Ossipov MH, Vanderah TW, Porreca F, Negri L.  2012.  Mechanisms of Bv8-induced biphasic hyperalgesia: increased excitatory transmitter release and expression.. Neurosci Lett. 521(1):40-5.

Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.  2012.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.. J Neuroimmunol. 244(1-2):23-31.

Pajouhesh H, Feng Z-P, Zhang L, Pajouhesh H, Jiang X, Hendricson A, Dong H, Tringham E, Ding Y, Vanderah TW et al..  2012.  Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.. Bioorg Med Chem Lett. 22(12):4153-8.

Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV.  2012.  Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.. Eur J Pharmacol. 684(1-3):64-70.

Lochhead JJ, McCaffrey G, Sanchez-Covarrubias L, Finch JD, DeMarco KM, Quigley CE, Davis TP, Ronaldson PT.  2012.  Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain.. Am J Physiol Heart Circ Physiol. 302(3):H582-93.

Lee YSun, Kulkarani V, Cowell SM, Ma S-W, Davis P, Hanlon KE, Vanderah TW, Lai J, Porreca F, Vardanyan R et al..  2011.  Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.

Tumati S, Roeske WR, Largent-Milnes TM, Vanderah TW, Varga EV.  2011.  Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.. J Neurosci Methods. 199(1):62-8.

Tumati S, Roeske WR, Largent-Milnes T, Wang R, Vanderah TW, Varga EV.  2010.  Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.. Br J Pharmacol. 161(1):51-64.

Tumati S, Milnes TLargent, Yamamura HI, Vanderah TW, Roeske WR, Varga EV.  2008.  Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.. Eur J Pharmacol. 601(1-3):207-8.

Largent-Milnes TM, Guo W, Wang H-Y, Burns LH, Vanderah TW.  2008.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.. J Pain. 9(8):700-13.